Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by indaknownewfieon Nov 25, 2019 5:54pm

127 Views

Post# 30391058

RE:If only

JamesNeven1983 wrote: If only it was Kalytera Therapeutics.. soon soon https://finance.yahoo.com/news/sorrento-therapeutics-inc-received-rejected-120010611.html

Our time will come brother. If anything it serves as a stark reminder to manyto buy while it is at an all time low.. Sorrento jumped 95% today after the announcement and the company rejected $5 a share in cash saying it undervalued them. They sit at just over $3 per share now. So they could double again. That is what could happen when Kalytera announces the Echelon's assessment of the three unsolicited offers. We will see massive jumps. If you look at the volume of sorrento shares traded today on Nasdaq is was around 75 million. Astronomical!!!!

Bullboard Posts

2024, a breakthrough year for silver